Paradigm Biopharmaceuticals (ASX:PAR) has been granted a trading halt by the ASX, with its shares placed in pre-open.
Paradigm requested the halt pending the company reviewing the status of its current clinical trial in allergic rhinitis.
The halt will remain in place until the opening of trade on Monday 19th June 2017, or earlier if an announcement is made to the market.